A multidisciplinary team at Yale, led by Yale Cancer Center members, has defined a subgroup of genetic mutations that are present in a significant number of melanoma skin cancer cases. Their findings shed light on an important mutation in this deadly disease and may lead to more targeted anti-cancer therapies. The role of mutations in numerous genes and genomic changes in the development of melanoma is well established and continues to be the focus of intense research.
No comments yet. Be the first to comment!
0 Comments